阿托伐他汀预防大鼠对比剂肾病的研究

目的探讨阿托伐他汀对大鼠对比剂肾病的保护作用及最佳给药时间。方法 32只SD大鼠随机分为正常对照组、造模组、阿托伐他汀1组和阿托伐他汀2组共四组,每组8只。按要求分别在不同时间点给予药物干预。检测大鼠肾功能(血肌酐及尿素氮)。光镜下,观察肾组织病理改变并进行肾小管损伤评分。结果 (1)与造模组比较,阿托伐他汀1组Scr、BUN降低(P<0.05),而阿托伐他汀2组Scr、BUN具有下降趋势,但差异无统计学意义(P>0.05)。阿托伐他汀1组Scr、BUN低于阿托伐他汀2组(P<0.05)。(2)在光镜下,可以观察到阿托伐他汀1组肾小管病变最轻,造模组肾小管病变最重,即阿托伐他汀1组肾小管损伤评分低于阿托伐他汀2组与造模组(P<0.05);阿托伐他汀2组损伤评分低于造模组,但差异无统计学意义(P>0.05)。结论阿托伐他汀对由对比剂引起的大鼠急性肾损伤具有预防作用,且作用效果与给药时间相关,但其最终机制尚未明确,我们需要在今后的临床实践中进一步研究证实。

Study of atorvastatin prevention of contrast-induced nephropathy on rats

Objective To explore protective effect and best administration time of atorvastatin on contrast induced nephrapathy rats. Methods 32 adult SD rats were selected and randomly divided into four groups with eight rats in each one： control group, Atorvastatin group 1, Atorvastatin group 2 and model group. The rats were given the drug intervention according to the requirements. The rats renal function was tested, pathological changes of glomerular and renal tubular injury scores for different times and atorvastatin intervention were observed under light microscope. Results （1）Compared with model group, Scr and BUN were decreased atorvastatin group 1 （P〈0.05）, and atorvastatin group 2 had a downward trend, but there was no statistical significance （P〉0.05）. Scr and BUN in atorvastatin group 1 were lower than that in atorvastatin group 2 （P〈0.05）. （2）Under light microscope, glomerular lesions was lightest in atorvastatin group 1 and most severe lesions in model. Namely, atorvastatin group 1 renal tubular injury scores was less than atorvastatin group 2 （P〈0.05）. Injury scores in atorvastatin group 2 were less than that in model group, but there was no statistical significance （P〉0.05）.Conclusion It is suggested that the atorvastatin could prevent the contrast-induced nephropathy on rats, and the effect was related with the injection time. However, the ending mechanism of atorvastatins should be further studied in the clinical practices.